Edition:
United Kingdom

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

834.00GBp
4:40pm BST
Change (% chg)

0.50 (+0.06%)
Prev Close
833.50
Open
834.50
Day's High
834.50
Day's Low
833.00
Volume
406,029
Avg. Vol
1,257,589
52-wk High
853.00
52-wk Low
467.40

Latest Key Developments (Source: Significant Developments)

BTG Says NHS England Expands Loco-Regional Treatment Options For Colorectal Cancer Patients With Metastatic Disease
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - BTG PLC ::NHS ENGLAND EXPANDS LOCO-REGIONAL TREATMENT OPTIONS FOR COLORECTAL CANCER PATIENTS WITH METASTATIC DISEASE 1.EFFECTIVE 1 APRIL 2019, NHS ENGLAND WILL ROUTINELY COMMISSION SELECTIVE INTERNAL RADIATION THERAPY FOR COLORECTAL CANCER PATIENTS.  Full Article

Boston Scientific CEO Says Expects To Deliver Double Digit EPS Growth In 2018
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Boston Scientific Corp ::CEO SAYS EXPECT TO DELIVER DOUBLE DIGIT EPS GROWTH IN 2018 - JP MORGAN CONF.CEO SAYS NO CHANGES TO LAUNCH OF LOTUS SYSTEM; ON TRACK FOR Q1 LAUNCH IN EUROPE AND MID-YEAR IN U.S..CEO SAYS BTG PLC'S <<>> INTERVENTIONAL MEDICINE BUSINESS BRINGS MOST VALUE TO BSX.CEO EXPECTS TAX RATE OF 13 PERCENT AND FOREIGN EXCHANGE IMPACT TO BE NEUTRAL IN 2019 - JP MORGAN CONF.CEO SAYS WILL EXCEED ABOUT $1.1 BILLION IN RESEARCH AND DEVELOPMENT, WITH 30 PERCENT OF SPENDING IN CLINICAL PROJECTS - JP MORGAN CONF.  Full Article

BTG Says French Ministry Of Health And Social Affairs To Reimburse Therasphere For Patients
Friday, 21 Dec 2018 

Dec 21 (Reuters) - BTG PLC ::FRENCH MINISTRY OF HEALTH AND SOCIAL AFFAIRS WILL REIMBURSE THERASPHERE FOR PATIENTS WITH LIVER CANCER WHO MEET CERTAIN CRITERIA.  Full Article

BTG Says Invesco Contacted Bravo Bidco To Request Insertion Of Clause
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - BTG PLC ::UPDATE ON IRREVOCABLE UNDERTAKING.INVESCO CONTACTED BRAVO BIDCO TO REQUEST INSERTION OF CLAUSE SPECIFYING UNDERTAKING WILL EXPIRE ON AUG 20 AUGUST 2019.BRAVO BIDCO HAS AGREED TO INVESCO REQUEST AND CERTAIN OTHER NON-SUBSTANTIVE AMENDMENTS TO CORRECT CERTAIN TYPOGRAPHICAL AND CLERICAL ERRORS.  Full Article

FDA Approves Crofab Product Improvements
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - BTG PLC ::FDA APPROVES CROFAB PRODUCT IMPROVEMENTS.BTG PLC - FDA APPROVED UPDATING SHELF LIFE OF CROFAB CROTALIDAE POLYVALENT IMMUNE FAB TO 60 MONTHS.  Full Article

BTG says CFO Rolf Soderstrom to step down as executive director
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - BTG PLC ::THAT AFTER 10 YEARS AS CHIEF FINANCIAL OFFICER (CFO) AT BTG, ROLF SODERSTROM IS TO STEP DOWN AS AN EXECUTIVE DIRECTOR OF COMPANY​.‍INTENDS TO APPOINT DUNCAN KENNEDY TO SUCCEED ROLF AS CFO ON 1 JANUARY 2018​.‍ROLF WILL REMAIN WITH COMPANY UNTIL COMPLETION OF A SMOOTH HANDOVER TO DUNCAN, WHICH IS EXPECTED TO BE CONCLUDED BY 31 MARCH 2018​.  Full Article

BTG H1 ‍adjusted operating profit of 99.1 mln stg vs 78.8 mln stg
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Btg Plc :H1 REVENUE 341.3 MILLION STG.H1 ‍ADJUSTED OPERATING PROFIT OF 99.1 MILLION STG VERSUS 78.8 MILLION STG YEAR AGO​.BTG PLC - ‍FURTHER GROWTH IS EXPECTED IN H2 IN INTERVENTIONAL MEDICINE PRODUCT SALES ​.BTG PLC - ‍PHARMACEUTICALS REVENUES IN H2 WILL REFLECT H1-WEIGHTED SEASONALITY OF CROFAB AND FEWER ANTICIPATED EXPIRY ORDERS FOR DIGIFAB COMPARED WITH H2 2016/17​.‍GROUP'S OVERALL OUTLOOK FOR FULL YEAR TO 31 MARCH 2018 REMAINS UNCHANGED​.  Full Article

BTG Plc reiterates full year product sales guidance
Thursday, 5 Oct 2017 

Oct 5 (Reuters) - BTG PLC ::‍GROUP REITERATES ITS PRODUCT SALES GUIDANCE FOR FULL YEAR.‍SPECIALTY PHARMACEUTICALS IS EXPECTED TO GROW BY LOW-TO-MID SINGLE DIGITS AT CER IN FY, WEIGHTED AS EXPECTED TO FIRST HALF.​.‍"DELIVERED A GOOD PERFORMANCE IN FIRST HALF OF YEAR, WITH DOUBLE-DIGIT CER 1 PRODUCT SALES GROWTH"​.CONSIDERING OPTIONS, INCLUDING APPEALING RULING AND LEVEL OF DAMAGES AWARDED REGARDING LITIGATION WITH WELLSTAT THERAPEUTICS CORPORATION​.  Full Article

BTG acquires Roxwood Medical
Thursday, 5 Oct 2017 

Oct 5 (Reuters) - BTG Plc :ACQUIRED ROXWOOD MEDICAL, A PROVIDER OF ADVANCED CARDIOVASCULAR SPECIALTY CATHETERS.‍WILL PAY UP TO $80M IN CASH TO ACQUIRE ROXWOOD​.‍TRANSACTION IS EXPECTED TO BE ACCRETIVE TO ADJUSTED EPS FROM SECOND FULL YEAR OF OWNERSHIP​.  Full Article

BTG sees double-digit product sales growth in medium term
Tuesday, 16 May 2017 

May 16 (Reuters) - Btg Plc :Fy revenue 570.5 million stg.Are well positioned to capture further value in growing interventional medicine space and to deliver sustained business growth.Adjusted operating profit up 13% at CER in 2016/17.Strong financial position with £155.5m of cash at 31 March 2017.IFRS operating profit and IFRS EPS impacted by previously announced legal settlement (£28.0m).Expect to see product sales at mid-to-high teens percentage growth.Looking beyond 2017/18, we expect to deliver continued double-digit product sales growth.  Full Article

UPDATE 2-Edward Lifesciences pays Boston Scientific $180 mln to end patent row

Jan 15 Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.